Day One Biopharmaceuticals (DAWN) investor relations material

Key business highlights

• Achieved over $155 million in revenue in 2025, marking 170% year-over-year growth, with Q4 revenue exceeding $52 million and 37% quarter-over-quarter growth.

• Provided 2026 net product revenue guidance of $225–$250 million, targeting about 50% year-over-year growth at the midpoint.

• OJEMDA is positioned as the main driver of durable growth, with ongoing expansion into new indications and pipeline programs.

• Frontline trial enrollment for OJEMDA expected to complete in the first half of the year, with key data readouts anticipated.

• Emphasized a strong, execution-focused team and seamless integration of new assets.

Product performance and launch metrics

• New patient starts (NPS) grew 25% in the second half of 2025 compared to the first half, driven by additional data and physician education.

• Duration of therapy averages 17 months (mean) and 19 months (median), supporting sustained growth.

• Persistence is expected to improve with more data, physician experience, and better management of side effects like rash.

• Second line use is increasing as familiarity grows, with education and data dissemination as key priorities.

• Recent data show nearly 80% of children remain off therapy for a year after completing OJEMDA, with a median time to next therapy of almost 43 months.

Pipeline and R&D updates

• DAY301 (PTK7-targeted ADC) began dose escalation in late 2024, with initial clinical data expected in the back half of 2025.

• Early antitumor signals and a favorable safety profile observed, with plans to expand into tumor-specific cohorts.

• Emi-Le (B7-H4-targeted ADC) for adenoid cystic carcinoma (ACC) will have updated data mid-year, focusing on safety and efficacy.

• ACC chosen as the lead indication due to strong clinical data and urgent unmet need; TNBC remains a possible future target.

• Emi-Le’s safety profile shows no hematologic, neuropathic, or ocular toxicity, which is notable for its class.